ARCELLX ($ACLX) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$1.13 per share, missing estimates of -$0.77 by $0.36. The company also reported revenue of $8,130,000, missing estimates of $20,458,140 by $-12,328,140.
You can see Quiver Quantitative's $ACLX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARCELLX Insider Trading Activity
ARCELLX insiders have traded $ACLX stock on the open market 53 times in the past 6 months. Of those trades, 0 have been purchases and 53 have been sales.
Here’s a breakdown of recent trading of $ACLX stock by insiders over the last 6 months:
- KAVITA PATEL has made 0 purchases and 22 sales selling 70,979 shares for an estimated $6,964,978.
- RAMI ELGHANDOUR (SEE REMARKS) has made 0 purchases and 7 sales selling 97,244 shares for an estimated $6,884,355.
- MICHELLE GILSON (CHIEF FINANCIAL OFFICER) has made 0 purchases and 15 sales selling 42,728 shares for an estimated $3,585,081.
- CHRISTOPHER HEERY (CHIEF MEDICAL OFFICER) has made 0 purchases and 9 sales selling 30,662 shares for an estimated $2,226,679.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ARCELLX Hedge Fund Activity
We have seen 107 institutional investors add shares of ARCELLX stock to their portfolio, and 99 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 1,477,360 shares (+22.8%) to their portfolio in Q4 2024, for an estimated $113,298,738
- RA CAPITAL MANAGEMENT, L.P. added 935,848 shares (+50.5%) to their portfolio in Q4 2024, for an estimated $71,770,183
- VANGUARD GROUP INC added 867,996 shares (+35.3%) to their portfolio in Q4 2024, for an estimated $66,566,613
- SUVRETTA CAPITAL MANAGEMENT, LLC removed 689,950 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $52,912,265
- JANUS HENDERSON GROUP PLC removed 454,858 shares (-22.6%) from their portfolio in Q4 2024, for an estimated $34,883,060
- PERCEPTIVE ADVISORS LLC removed 409,781 shares (-10.5%) from their portfolio in Q4 2024, for an estimated $31,426,104
- PARADIGM BIOCAPITAL ADVISORS LP added 371,601 shares (+9.3%) to their portfolio in Q4 2024, for an estimated $28,498,080
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARCELLX Analyst Ratings
Wall Street analysts have issued reports on $ACLX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Benchmark issued a "Positive" rating on 12/09/2024
- Bank of America Securities issued a "Buy" rating on 12/09/2024
To track analyst ratings and price targets for ARCELLX, check out Quiver Quantitative's $ACLX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
